A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

“…A recent Dutch phase III trial compared first-line PLD versus capecitabine in elderly patients with MBC but had to be closed prematurely due to slow accrual and lack of supply of PLD. In the Dutch phase III trial, PLD and capecitabine demonstrated comparable efficacy, the number of geriatric conditions correlated with grade 3–4 toxicities, and frailty correlated with shorter survival [24, 25]. In our phase III PELICAN trial, efficacy of first-line PLD was neither superior nor non-inferior to capecitabine in patients with MBC, as reflected by TTP (HR = 1.08; P  = 0.67) and OS (HR = 1.12; P  = 0.53).…”

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

“…with paclitaxel, docetaxel, gamcitabine, and platinum drugs) is more effective for treating patients with human epidermal growth factor receptor 2 (HER-2) positive locally advanced or recurrent breast cancer, and the use of liposome as a carrier may significantly reduce the cardiac toxicity of the drugs. A phase-II study has suggested that after Smorenburg et al, 2014 6 cycles of treatment in combination with PLD (administered at 30 mg/m 2 every three weeks), gemcitabine, and paclitaxel, better therapeutic efficacy was detected in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy (Artioli et al, 2010). In a phase-II clinical study by Gogas et al (2002) suggested that 71% of patients were remitted after 6 cycles of combined therapy.…”

“…The research suggested that this combined regime was more suitable for elderly patients with metastatic breast cancer. In their phase-III clinical study, Smorenburg et al (2014) compared PLD (administered at 45 mg/m 2 every four weeks) with capecitabine in first-line chemotherapy of elderly patients with metastatic breast cancer in terms of their therapeutic efficacy and safety, while the patients were mostly HER-2 negative. The results indicated that both drugs were similar in therapeutic effects and safety among elderly patients, whereas the patients over 80 years could seldom undertake the chemotherapy.…”

Vers une approche multidisciplinaire optimale du traitement du cancer du sein chez les patientes plus âgées

“…Deux études ont été analysées concernant l'efficacité et la toxicité de diverses doses de paclitaxel chez les femmes âgées atteintes d'un cancer du sein métastatique et on a constaté que les patientes de 65 ans et plus obtenaient des bénéfices similaires aux patientes plus jeunes pour ce qui est de la survie globale et de la survie sans progression (Lichtman et al, 2012). D'autres études ont indiqué de bons taux de réponse et des bénéfices quant à la survie sans progression avec la capécitabine, le paclitaxel, l'épirubi-cine et la doxorubicine pégylée, avec un niveau acceptable de toxicité (Bajetta et al, 2005;Del Mastro et al, 2005;Feher et al, 2005;Smorenburg et al, 2014). Selon les lignes directrices de la SIOG, la chimiothérapie pour le cancer du sein métasta-tique est indiquée chez les patientes plus âgées dont la tumeur est négative en récepteurs des oestrogènes lorsque cette tumeur résiste à l'hormonothérapie ou progresse rapidement (Biganzoli et al, 2012).…”